{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:47:43Z","timestamp":1787496463952,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Apatinib is a systemic therapeutic agent for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA). Its efficacy can be enhanced by applying it as a combination therapy, but the evidence supporting its combination application as a second-line treatment is not well documented. In the current study, we aimed to assess the efficacy and safety profile of apatinib, both as a monotherapy and in combination regimens, for second-line treatment of GAC and GEJA in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort analysis, we analyzed clinical data from 96 patients with advanced GAC or GEJA who received second-line apatinib monotherapy or combination therapy. Cox regression analysis was performed to identify prognostic factors influencing clinical outcomes of different treatment approaches (apatinib combination with other drugs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results indicated that the overall objective response rate (ORR) and disease control rate (DCR) for second-line apatinib therapy were 19.8% and 31.3%, respectively. The median progression-free survival (mPFS) was 4.8 months (95% CI: 4.3-6.2m), while the median overall survival (mOS) was 10.3 months (95% CI: 8.9-12.4m). Multivariable Cox regression analysis identified gender, liver metastasis, and peritoneal metastasis as independent predictors of inferior PFS and OS outcomes. In terms of safety, the primary adverse reactions included myelosuppression, elevated AST and ALT levels, hypertension, hand-foot syndrome, hyperbilirubinemia, proteinuria, fatigue, and vomiting, with a low incidence of grade 3\u20134 toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Apatinib-based combination therapy significantly enhances both progression-free survival and overall survival in patients with advanced gastric cancer when compared to monotherapy, while also demonstrating a safe and reliable profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1587069","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:12:50Z","timestamp":1745971970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of apatinib in combination treatment versus apatinib as second-line treatment for advanced gastric cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yuanzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Peichun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.21147\/j.issn.1000-9604.2023.02.01","article-title":"Stomach cancer burden in China: epidemiology and prevention","volume":"35","author":"Yan","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i5.466","article-title":"Endoscopic Kyoto classification of helicobacter pylori infection and gastric cancer risk diagnosis","volume":"26","author":"Toyoshima","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2019.04.036","article-title":"Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features","volume":"166","author":"Bergquist","year":"2019","journal-title":"Surgery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: an analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in Her2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019-2021: A multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mfolfox6 in patients with Cldn18.2-positive, Her2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (Spotlight): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133247","article-title":"Her-2 positive gastric cancer: current targeted treatments","volume":"274","author":"Malla","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase iii study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0809-y","article-title":"A multicenter, randomized trial comparing efficacy and safety of paclitaxel\/capecitabine and cisplatin\/capecitabine in advanced gastric cancer","volume":"21","author":"Lu","year":"2018","journal-title":"Gastric Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12534","article-title":"N6-methyladenosine reader Hnrnpa2b1 recognizes and stabilizes neat1 to confer chemoresistance in gastric cancer","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/ijms19010043","article-title":"Angiogenesis and anti-angiogenic therapy in gastric cancer","volume":"19","author":"Nienhuser","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01034-0","article-title":"The integration of immune checkpoint inhibitors with Vegf targeted agents in advanced gastric and gastroesophageal adenocarcinoma: A review on the rationale and results of early phase trials","volume":"14","author":"Saeed","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00313-7","article-title":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (Rainbow-Asia): A randomised, multicentre, double-blind, phase 3 trial","volume":"6","author":"Xu","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: A single-arm, open label, phase ii clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1634\/theoncologist.2019-0164","article-title":"A single-arm, phase ii study of apatinib in refractory metastatic colorectal cancer","volume":"24","author":"Chen","year":"2019","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.21037\/atm-22-2752","article-title":"Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: A single-arm, open-label, prospective, multicenter study","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03174-9","article-title":"Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2, single-arm, prospective study","volume":"71","author":"Jing","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01425-3","article-title":"Pd-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: A single-center, single-arm, phase ii study","volume":"42","author":"Gou","year":"2024","journal-title":"Invest New Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11542","DOI":"10.1038\/s41598-022-15839-7","article-title":"The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019","volume":"12","author":"Song","year":"2022","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s10120-024-01494-6","article-title":"Global burden of young-onset gastric cancer: A systematic trend analysis of the global burden of disease study 2019","volume":"27","author":"Li","year":"2024","journal-title":"Gastric Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1055\/a-1728-5673","article-title":"Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: A population-based study","volume":"54","author":"Li","year":"2022","journal-title":"Endoscopy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-021-00412-7","article-title":"Mapping the genomic diaspora of gastric cancer","volume":"22","author":"Yeoh","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10852","article-title":"Germline cdh1 variants and lifetime cancer risk","volume":"332","author":"Ryan","year":"2024","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The chinese society of clinical oncology (Csco): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac086","article-title":"Phase ii study of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with advanced gastric cancer: Hgcsg1603","volume":"27","author":"Kawamoto","year":"2022","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1535592","article-title":"The safety of apatinib for the treatment of gastric cancer","volume":"17","author":"Geng","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025630","article-title":"Apatinib combined with S-1 as second-line therapy in advanced gastric cancer","volume":"100","author":"Qiu","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1072943","article-title":"Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: A prospective, multicenter phase ii trial","volume":"13","author":"Qu","year":"2023","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0903-9","article-title":"Apatinib: A review in advanced gastric cancer and other advanced cancers","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:12:51Z","timestamp":1745971971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":38,"alternative-id":["10.3389\/fonc.2025.1587069"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1587069","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"article-number":"1587069"}}